secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAXCYTE, INC. (MXCT)
CIK:        0001287098
Form:       8-K
Filed at:   2026-05-12T20:12:55+00:00
Accession:  0001104659-26-059399
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MaxCyte Q1 revenue $9.7M (-7% YoY); net loss narrows to $4.8M; board authorizes $10M buyback
--------------------------------------------------------------------------------

- Core revenue $6.2M (-25% YoY); SPL-related revenue rose to $3.4M from $2.1M.
- Net loss improved to $4.8M from $10.3M; EBITDA loss $5.1M vs $11.2M.
- Reiterated FY 2026 revenue guidance $30-32M (core $25-27M, SPL ~$5M).
- Board authorized $10M share repurchase program over one year.
- Cash, equivalents and investments $147.7M as of March 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926059399/0001104659-26-059399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1287098/000110465926059399/mxct-20260512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer